Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy.
Dillard P, Köksal H, Maggadottir SM, Winge-Main A, Pollmann S, Menard M, Myhre MR, Mælandsmo GM, Flørenes VA, Gaudernack G, Kvalheim G, Wälchli S, Inderberg EM.
Dillard P, et al. Among authors: gaudernack g.
Mol Ther. 2021 Mar 3;29(3):1199-1213. doi: 10.1016/j.ymthe.2020.11.019. Epub 2020 Nov 17.
Mol Ther. 2021.
PMID: 33212301
Free PMC article.